J.B. Pharma delivered a strong Q3 FY26 performance characterized by significant margin expansion and market-beating growth in the domestic segment. The company continues to transition towards a chronic-heavy portfolio in India while seeing a rebound in international formulation exports, particularly in Russia and South Africa. Strategic focus remains on the pending merger with Torrent and scaling the CDMO and Ophthalmology platforms.
vs Q4 FY26
Notable Quotes from the Call
Most Confident Moment
Management citing specific brand growth numbers like Cilacar at 25%+ and Cilacar-T at 33% to demonstrate chronic segment strength.
Least Confident Moment
Deflecting questions on specific synergy values from the Torrent merger, stating they would not like to comment as of now.
| Metric | Value | YoY |
|---|---|---|
| Revenue | ₹1.1K Cr | +11.0% YoY |
| Operating EBITDA | ₹305 Cr | +13.0% YoY |
| EBITDA Margin | 28.7% | — |
| PAT | ₹198 Cr | +22.0% YoY |
| Gross Margin | 69.1% | — |
| Other Income | ₹18 Cr | +125.0% YoY |
Segment Breakdown
Share of Revenue
| Metric | Latest | Trend |
|---|---|---|
| Revenue(crores) | 904 | |
| Net Profit(crores) | 146 | |
| Gross Margin | 70% | |
| Operating EBITDA(crores) | 305 | |
| EBITDA Margin | 28.7% |
| Category | Target | Priority |
|---|---|---|
| Margin | Operating Margins→27% to 29% | High |
| Market Share | Domestic Growth vs IPM→200 to 300 bps better | High |
| Revenue | CDMO Run Rate→₹115 crore to ₹120 crore | High |
| Revenue | CDMO Growth→10% to 12% | Medium |
| Revenue | Ophthalmology Run Rate→₹17 crore to ₹18 crore | Medium |
| Other | ESOP Charge→₹40 crore | Medium |
| Severity | Risk |
|---|---|
medium | Slowdown in Acute/Gastro Portfolio Management noted a slowdown in the acute gastro segment, which impacted overall domestic growth rates. Both |
medium | One-time ESOP Charge A potential ₹40 crore charge in Q4 FY26 if the change of control (merger) event occurs. Management |
low | Regulatory/Merger Completion Timeline Analysts questioned the 6-9 month gap between deal closure and merger; management cited it as a normal process speed. Analyst |
Areas of Evasion(2)
J.B. Pharma's domestic business grew 10% YoY to ₹620 crore, consistently outperforming the IPM by 200-300 bps. The growth is heavily supported by the chronic portfolio, with flagship brands like Cilacar and Nicardia growing at 25%+ and 30% respectively. While the acute segment, particularly gastro, saw a seasonal slowdown, the company's focus on chronic therapies continues to provide a stable and high-margin revenue base.
International formulation revenue surged 20% YoY to ₹306 crore, driven by strong demand in Russia, South Africa, and the U.S. Management noted a healthy order book for Q4, guiding for high single-digit growth for the full year in the international segment. This rebound compensates for the relatively flat performance in the CDMO category, which faced a high base effect from the previous year.
Gross margins expanded by 200 bps to 69.1%, while operating EBITDA margins reached 28.7%. This improvement was attributed to a better product mix (higher chronic share), price hikes of approximately 7% taken during the quarter, and stable raw material costs. Management remains confident in maintaining EBITDA margins between 27% and 29% for the full fiscal year.
The pending merger with Torrent is progressing at 'normal speed,' with closure expected in Q4 FY26. Management clarified that while the deal might close in Q4, the full legal merger process could take an additional 6 to 9 months. A significant one-time📎 ESOP charge of approximately ₹40 crore is anticipated in Q4 upon the change of control, which investors should factor into short-term earnings expectations.
The company is actively scaling its Ophthalmology and CDMO platforms. Ophthalmology is targeted to reach a monthly run rate of ₹17-18 crore within the next 3-4 months. Meanwhile, the CDMO business is expected to maintain a quarterly run rate of ₹115-120 crore for the current year, with a projected growth of 10-12% in FY27 as new capacities and efficiencies kick in.